Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer
Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.
Related Articles
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Sorafenib Plus Valproic Acid and Sildenafil Proves Active in High-Grade Glioma – Oncology Nurse Advisor
“Our data suggest that the combination of sorafenib tosylate, valproic acid, and sildenafil requires additional clinical development in the recurrent glioma population,” the researchers wrote.
Assessing Cosibelimab’s Future in Cutaneous Squamous Cell Carcinoma
According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment…
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Improving sickle cell nephropathy with concurrent GBT1118 & losartan treatment
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, comments on the concurrent administration of GBT1118 & losartan in a mouse model of kidney disease…
Daughter honors dad by giving blood in his memory
After her dad died of liposarcoma, Valeria Medrano wanted to do something to give back. She began donating blood to MD Anderson Blood Bank through…
Boosting antitumor activity with oncolytic viruses prior to ICI immunotherapy
Roger Li, MD, H. Lee Moffitt Cancer Center, Tampa, FL, provides a brief overview on the joint mechanism of action for oncolytic viruses and immune…
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors
This Review describes why comprehensive molecular biomarker testing is now required for the accurate diagnosis and grading and prognostication of central nervous system tumors.
Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer
Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.